Mazdutide
ALSO KNOWN AS · IBI362 · LY3305677
An oxyntomodulin-based GLP-1 and glucagon dual agonist developed primarily for the Chinese market, with approval filings for obesity and type 2 diabetes.
Background
Mazdutide is derived from oxyntomodulin, a naturally occurring proglucagon product that activates both the GLP-1 and glucagon receptors. Phase 3 trials in Chinese adults with obesity reported mean weight reductions above 14% at 48 weeks.
PRIMARY SOURCES
- 01Mazdutide GLORY-1 Phase 3— ClinicalTrials.gov
Educational reference only. Trial figures are protocol-condition means, not individual predictions. Investigational compounds are not approved medicines and have no legitimate consumer supply route.